Xywav

*
*
*
*
*
*
*
4
Xywav, bụ ọgwụ a na-eji agwọ cataplexy ma ọ bụ ụra ehihie gabigara ókè (EDS). O nwere nzube magburu onwe ha na kpo ngwakọta nke nnu oxybate, ya bụ Calcium oxybate. A na-aṅụ ya n'ọnụ.

N'ịbụ nke ụlọ ọrụ Jazz Pharmaceuticals mepụtara site na iji bịa na ímé ihe, a kwadoro ya maka iji ya mee ihe na United States na July 2020.

 Ojiji ọgwụ 
A na-egosi Xywav maka ọgwụgwọ nke cataplexy nke ụwa họrọ site na iji bịa na na ndị dị afọ asaa ma ọ bụ karịa na narcolepsy.

N'ọnwa Ọgọstụ 2021, U.S. Food and Drug Administration (FDA) kwadoro Xywav maka ọgwụgwọ nke idiopathic hypersomnia.

 Mmetụta Ndị Ọzọ 

 Nsogbu iku ume 
Ịdị nwayọ iku ume, Nsogbu iku ume, apnea ụrahttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212690s000lbl.pdf

 Nsogbu Ahụ Ike Uche 
Mgbagwoju anya, Hallucination, echiche ndị a na-adịghị ahụkebe ma ọ bụ ndị na-enye nsogbu (echiche na-adịghị mma), nchegbu, ịda mbà n'obi, echiche ma ọ bụ omume igbu onwe onye, ike ọgwụgwụ na-arịwanye elu, mmetụta nke obi amamikpe ma ọ bụ enweghị uru, Ihe isi ike ilekwasị anyahttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212690s000lbl.pdf

 Ndị ọzọ 

 Ọha na omenala 

 Ọnọdụ iwu 
U.S. Food and Drug Administration (FDA) nyere Xywav aha ọgwụ na-enweghị nne na nna na Nọvemba 1994. FDA nyere nkwado nke Xywav na Jazz Pharmaceuticals plc n'ọnwa Ọgọstụ 2021.

 Aha ndị ọzọ 

 Ntụaka